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Background: Natalizumab is highly effective in reducing multiple sclerosis disease activity; however it carries a risk
of progressive multifocal leukoencephalopathy, that represents the main reason of drug discontinuation. After
natalizumab withdrawal, reactivation of disease is soon observed and, until now, it is not known which treatment
strategy should be followed after natalizumab discontinuation. Aim of this study is to evaluate rituximab efficacy in
controlling disease activity after natalizumab withdrawal.
Case Presentation: Ten relapsing-remitting multiple sclerosis patients treated with natalizumab stopped it for the
high risk of progressive multifocal leukoencephalopathy and started rituximab after a wash out period of two
months; Second cycle of rituximab was planned in case of CD19+ cells increase and/or disease reactivation; brain
MRI was performed before starting rituximab and then at six and twelve months after it.
Conclusions: All the patients showed disease stability during the wash out period.
Radiological stability was observed at 6 and at 12 months in all the patients; during the follow up two patients had
exacerbation of sensitive symptoms without evidence of brain MRI activity.
This study gives evidence of rituximab efficacy in abolishing disease reactivation after natalizumab withdrawal.
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Natalizumab has been confirmed as highly effective in
reducing multiple sclerosis (MS) disease activity.
However, it carries a risk of progressive multifocal
leukoencephalopathy (PML), an opportunistic disease
with high morbidity, that represents the major cause
of natalizumab interruption.
Upon withdrawing natalizumab, resumption of disease
activity is soon observed [1, 2]. An unsolved problem is
the lack of therapies able to abolish the risk of disease
reactivation after natalizumab withdrawal.
Many strategies aiming at reducing the risk of disease
reactivation have been tried; switching to first-line
therapies or high dose corticosteroids failed to control
the disease; literature data about the use of fingolimod* Correspondence: simona.malucchi@gmail.com
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short wash out period after natalizumab interruption [3, 4].
In this report we want to share our experience about
the use of rituximab after natalizumab withdrawal with
the aim to evaluate its efficacy in controlling disease
course.
Case Presentation
Ten RR-MS patients (8 women and 2 male) have been
treated with natalizumab for a median number of 38
infusions (range 22–76); patients had a median number
of 2 relapses in the year preceding natalizumab in spite
of disease modifying drugs (DMDs) and full response to
natalizumab (neither clinical nor radiological activity
during treatment); demographic and clinical characteristics
are presented in Table 1. All the patients had high risk of
PML, due to the association of a stratify index >1.5 and the
elevated number of infusions. After consultation between
neurologist and patient, decision to stop natalizumab was
taken and patients have been proposed to switch tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Demographic and clinical characteristics
Gender Age at
natalizumab start






Brain MRI at 6 months
after rituximab
Brain MRI at 12 months
after rituximab
F 29 2 35 1.5 unchanged unchanged
F 44 2 76 3.5 unchanged unchanged
F 32 1 27 2.0 unchanged unchanged
F 38 2 69 2.0 unchanged unchanged
M 25 1 37 4.5 unchanged unchanged
F 33 2 39 3.5 unchanged unchanged
F 40 1 22 2.0 unchanged unchanged
F 30 2 67 3.5 unchanged n.a.
F 35 2 71 2.0 unchanged n.a.
M 32 2 30 7.0 unchanged unchanged
n.a. not available (follow up <1 year)
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formed consent was obtained from each patient; as the use
of rituximab was off label, approval was obtained from the
local ethics committee of the University Hospital San
Luigi.
In our real-world clinical study median wash out
period was 3.2 months (range 2–4.2 months).
The choice of rituximab was due to the impossibility
of using fingolimod, because of cardiologic contraindica-
tion (2 patients), or patients’ refusal (8 patients).
Each patient underwent gadolinium-enhanced brain
MRI scan after the last infusion of natalizumab and two
months later, in order to exclude signs suggestive for
PML; than brain MRI was performed six and twelve
months after rituximab infusion; MRI was performed in
the same 1.5 T scanner using the same protocol for each
patients; protocol included axial T2-weighted scans,
coronal Flair-weighted scans, DWI sequences and post-
contrast T1-weighted scans.
Rituximab was administered at the dosage of 375 mg/mq
once/week for 4 weeks (I cycle); blood sample was taken
monthly in order to count CD19+ cells; second cycle at the
dosage of 1000 mg at day 0 and 15 was planned in case of
CD19+ increase and/or clinical or radiological disease
reactivation.
Patients started rituximab from October 2013 to May
2014; median follow up after rituximab was 15.8 months
(range 11.5–18.5 months).Results
No patient had disease reactivation during the wash out
period; brain MRI performed two months after the last
natalizumab infusion was unchanged compared to the
one performed immediately after the last infusion.
A brain MRI performed six months after rituximab
infusions did not show contrast-enhancing lesions or anincrease in the number of T2 lesions compared to the
brain MRI that had been performed after the last
natalizumab infusion. In patients with a follow up of one
year (8 patients), brain MRI performed 12 months after
rituximab was unchanged.
No patient experienced clinical rebound; two out of ten
had a worsening of pre-existing sensitive symptoms: the
first patient had an exacerbation of paresthesia in left
limbs six months after rituximab, the second had exacer-
bation of paresthesia in left face nine months after rituxi-
mab; both patients were treated with intravenous steroids
for 3 days; in both cases CD19 at the time of clinical re-
lapse were detectable and II cycle of rituximab was admin-
istered; brain MRI in both cases showed disease stability.
Compared to EDSS after the last natalizumab infusion,
EDSS was unchanged at six months in all the patients
and at 12 months in patients with one year follow up.
Conclusions
This is a preliminary study, conducted on a small number
of patients, aiming at the evaluation of rituximab efficacy
after natalizumab withdrawal. The choice of rituximab
was due to two main reasons: the evidence of efficacy in
aggressive RR-MS patients [5] and the minor risk of PML
compared to that of natalizumab [6, 7].
Furthermore, the use of rituximab was due to the
impossibility of using fingolimod, because of bradycardia
in 2 patients and patients’ refusal in the other 8 patients;
the use of ciclophosphamide was not taken into consid-
eration because our study population was characterized
by young people with desire for parenthood; patients
would have to undergo fertility preservation procedures
that would have extended the time of drug initiation.
Alemtuzumab was not yet available at the time the study
was conducted, so its use was not allowed.
This work shows rituximab is highly efficacious in con-
trolling disease course after natalizumab discontinuation,
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vation at six months after rituximab infusion, that corres-
pond to at least 8 months after natalizumab withdrawal.
Eight patients reached a follow up of one year and in
these patients MRI at 12 months showed persistence of
stability.
We observed two very mild relapses in two patients at
six and nine months after rituximab, without brain MRI
activity; in that circumstance the two patients showed an
increase of CD19+ cells that required the second cycle
of treatment.
A matter of concern in using Rituximab is the risk of
PML; compared to natalizumab very little data are known
about PML risk during rituximab treatment; data from
rheumatologic experience suggest a PML risk of 1/25000 in
rheumatoid arthritis affected patients treated with rituxi-
mab, including both JCV positive and negative patients (6),
whereas patients in our work had a risk of 1/120–1/145 [8].
Finally, at present there is no agreement on what
would be the best posological scheme for rituximab in
MS, including its duration. Different protocols have been
suggested and applied: 375 mg every week for 4 weeks
[9] or 1000 mg i.v. at day 0 and 15 [10]. Whatever
regimen is adopted and despite the lower risk of PML,
we believe that the use of rituximab to prevent
breakthrough disease after natalizumab should be
restricted to the first month after its discontinuation.
Later on additional strategies have to be found. In
our Clinic we are planning to use a standard regimen
with retreatment six month after the first cycle of
rituximab followed by a switch to another drug such
as dimethyl fumarate.
Despite the small number of patients this study has
two strong points: 1) patients had similar disease
features before natalizumab initiation with very active
course, and high risk of disease reactivation after its
interruption; brain MRI were performed at the same
time points with the same scanner and same protocol; 2)
it shows rituximab appears an efficacious strategy to
manage natalizumab discontinuation; therefore we think
our experience needs to be shared.Authors’ contributions
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